NCT06712459 Integrated Molecular and Clinical Profiling of Transformed Splenic Marginal Zone Lymphoma
| NCT ID | NCT06712459 |
| Status | Recruiting |
| Phase | — |
| Sponsor | International Extranodal Lymphoma Study Group (IELSG) |
| Condition | Transformed Splenic Marginal Zone Lymphoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-10-13 |
| Primary Completion | 2029-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-10-13 with a primary completion date of 2029-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Histological transformation in Splenic Marginal Zone Lymphoma (t-SMZL) represents an unmet clinical and biological need, invariably associated with poor prognosis and reduced overall survival. At the present time, there are no recommended treatments intended specifically to t-SMZL and little is known about t-SMZL genetic complexity. The aim of this study is to provide information that will help clinicians to better understand the complexity of the disease. The information gained from this study will also lead to more specific and effective treatment for patients with t-SMZL.
Eligibility Criteria
Inclusion Criteria: 1. Adults aged 18 years or older, regardless of the gender; 2. Diagnosis of HT of SMZL (both at baseline, co-occurring with diagnosis of SMZL, or during the natural history of the disease); 3. Availability of diagnostic tumor material (either frozen or FFPE) from spleen, lymph node, extra nodal site, peripheral blood or bone marrow collected at the time of histological transformation. Tumor material (either frozen or FFPE), from spleen, peripheral blood or bone marrow, collected at the time of SMZL diagnosis will be also collected, if available; 4. Availability of the baseline and follow-up annotations. Exclusion Criteria: * None
Contact & Investigator
Luca Arcaini, MD
STUDY CHAIR
Fondazione IRCCS Policlinico San Matteo
Frequently Asked Questions
Who can join the NCT06712459 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Transformed Splenic Marginal Zone Lymphoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06712459 currently recruiting?
Yes, NCT06712459 is actively recruiting participants. Contact the research team at ielsg@ior.usi.ch for enrollment information.
Where is the NCT06712459 trial being conducted?
This trial is being conducted at New York, United States, Leuven, Belgium, Paris, France, Pavia, Italy and 3 additional locations.
Who is sponsoring the NCT06712459 clinical trial?
NCT06712459 is sponsored by International Extranodal Lymphoma Study Group (IELSG). The principal investigator is Luca Arcaini, MD at Fondazione IRCCS Policlinico San Matteo. The trial plans to enroll 100 participants.